Literature DB >> 16361764

Organ-preserving multimodality management of squamous cell carcinoma of anal canal.

S V Deo1, N K Shukla, V Raina, B K Mohanti, Rajeev Sharan, Madhabananda Kar, G K Rath.   

Abstract

AIM: To study the efficacy of an organ-preserving, sequential chemoradiation therapy for squamous cell carcinoma of the anal canal, and of salvage surgery in those in whom this treatment fails.
METHODS: Forty biopsy-proven untreated patients (28 men) with squamous cell carcinoma of the anal canal received two cycles of chemotherapy using cisplatin and methotrexate, followed by 45 to 60 (median 50) Gy external beam radiotherapy. Salvage surgery was offered to those in whom this treatment failed. Overall survival, disease-free survival and colostomy-free survival were analyzed.
RESULTS: Most patients (n=35; 87%) had T3 or T4 lesions and 5 (12.5%) had involvement of inguinal nodes. Thirty-one patients (77.5%) had complete response after chemoradiation. Only three patients (7.5%) developed chemotherapy-related grade 3 mucositis and myelosuppression. Radiotherapy-related toxicity included grade III cystitis in one patient and grade III proctitis in three patients. Three patients had post-treatment anal stenosis requiring repeated dilatation and two had chronic non-healing ulcers at the anal verge. Nine patients had failure of chemoradiation or disease recurrence; of these, only 5 could undergo salvage surgery. After a median follow up of 60 months, overall survival, disease-free survival and colostomy-free survival were 80%, 77.5% and 72.5%, respectively.
CONCLUSION: Chemoradiation is effective in the treatment of squamous cell anal cancer and has acceptable toxicity. Surgical salvage may be useful in those with failure of this treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361764

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  4 in total

1.  Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy.

Authors:  José Luis López Guerra; Antonio José Lozano; Joan Pera; Cristina Gutiérrez; María Cambray; Ferran Ferrer; Ferran Guedea
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

2.  Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma.

Authors:  Maria G Zampino; Elena Magni; Maria C Leonardi; Luigi Santoro; Elena Petazzi; Cristiana Fodor; Giuseppe Petralia; Cristina Trovato; Franco Nolè; Roberto Orecchia
Journal:  BMC Cancer       Date:  2011-02-03       Impact factor: 4.430

3.  MITHRA - multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study.

Authors:  Luca Tagliaferri; Stefania Manfrida; Brunella Barbaro; Maria Maddalena Colangione; Valeria Masiello; Gian Carlo Mattiucci; Elisa Placidi; Rosa Autorino; Maria Antonietta Gambacorta; Silvia Chiesa; Giovanna Mantini; György Kovács; Vincenzo Valentini
Journal:  J Contemp Brachytherapy       Date:  2015-10-19

Review 4.  Gastrointestinal cancers in India: Treatment perspective.

Authors:  Nikhil Suresh Ghadyalpatil; Chopra Supriya; Patil Prachi; Dsouza Ashwin; Saklani Avanish
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.